Clinico-pathogenetic features of hyperplastic endometrial processes in women of perimenopausal age

1. Доброхотова Ю. Э., Сапрыкина Л. В. Гиперплазия эндометрия. М.: ГЭОТАР-Медиа, 2016. 90 с. [Dobrokhotova Yu.E., Saprykina L. V. Giperplaziya endometriya. M.: GEOTAR-Media, 2016. 90 s. (in Russian)]. 2. Ашрафян Л. А., Киселев В. И. Опухоли репродуктивных органов (этиология и патогенез). М.: Димитрейд График Групп, 2007. 216 с. [Ashrafyan L.A., Kiselev V. I. Opukholi reproduktivnykh organov (etiologiya i patogenez). M.: Di-mitreyd Grafik Grupp, 2007. 216 s. (in Russian)]. 3. Baak J. P., Mutter G. L., Robboy S. et al. The molecular genetics and morphometry-based endometrial in-traepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 WHO classification system // Cancer. 2005. Vol. 103 (11). P. 2304–2312. 4. Feng Y. Z., Shiozawa T., Miyamoto T. et al. BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression // Clin. Cancer Res. 2005. Vol. 1 (17). P. 6133–6138. 5. Савилова А. М., Юшина М. Н., Рудимова Ю. В. и др. Сравнительная характеристика мультипотентных мезенхимных стромальных клеток, выделенных из очагов эндометриоза человека и из эндометрия // Клеточные технологии в биологии и медицине. 2016. № 2. С. 132–137 [Savilova A.M., Yushina M. N., Rudimova Yu.V. i dr. Sravnitel’naya kharakteristika mul’tipotentnykh mezenkhimnykh stromal’nykh kletok, vydelennykh iz ochagov endometrioza cheloveka i iz endometriya // Kletochnyye tekhnologii v biologii i meditsine. 2016. № 2. S. 132–137 (in Russian)]. 6. Szotek P. P., Pieretti-Vanmarcke R., Masiakos P. T. et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness // Proc Natl Acad Sci USA. 2006. Vol. 103 (30). P.11154–11159. 7. Clarke M. F., Dick J. E., Dirks P. B. et al. Cancer stem cells–perspectives on current status and future directions: AACR Workshop on cancer stem cells // Cancer Res. 2006. Vol. 66 (19). P. 9339–9344. 8. Alvero A. B., Chen R., Fu H. H. et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance // Cell Cycle. 2009. Vol. 8 (1). P. 158–166. 9. Chan R. W., Schwab K. E., Gargett C. E. Clonogenicity of human endometrial epithelial and stromal cells // Biol Reprod. 2004. Vol. 70 (6). P. 1738–1750. 10. Bapat S. A. Human ovarian cancer stem cells // Reproduction. 2010. Vol. 140 (1). P. 33–41. 11. Fabian A., Vereb G., Szollosi J. The hitchhikers guide to cancer stem cell theory: markers, pathways and therapy // Cytometry A. 2013. Vol. 83 (1). P. 62–71. 12. Angelow S., Ahlstorm R., Yu A. S. Biology of claudins // Am J Physiol Renal Physiol. 2008. Vol. 295. P. 867–874. 13. Bischoff F. Z., Simpson J. L. Heritability and molecular genetic studies of endometriosis // Hum Reprod Update. 2000. Vol. 6 (1). P. 37–44. 14. Loverro G., Perlino E., Maiorano E. et al. TGF-beta 1 and IGF-1 expression in atrophic post-menopausal endometrium // Maturitas. 1999. Vol. 31 (2). P. 179–184. 15. Sivridis E., Giatromanolaki A. Prolifirative activity in postmenopausal endometrium: the lurcing potencial for giving rise to an endometrial adenocarcinoma // J Clin Pathol. 2004. Vol. 57 (8) P. 840–844. 16. Kryczek I., Liu S., Roh M. et al. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells // Int J Cancer. 2012. Vol. 130 (1). P. 29–39. 17. Rahadiani N., Ikeda J.— I., Mamat S. et al. Expression of aldehyde dehydrogenase 1 in endometrioid adenocarcinoma and its clinical implications // Cancer Sci. 2011. Vol. 102. P. 903–908. 18. Lu X., Lin F., Fang H. et al. Expression of a putative stem cell marker Musashi-1 in endometrium // Histol Histopathol. 2011. Vol. 26 (9). P. 1127–1133. 19. Gotte M., Wolf M., Staebler A. Increased expression of the adult stem cell marker Musashi-1 in endometriosis and endometrial-carcinoma // J Pathol. 2008. Vol. 215 (3). P. 317–329. 20. Gotte M., Greve B., Kelsch R. et al. The adult stem cell marker Musashi-1 modulates endometrial carcinoma cell cycle progression and apoptosis via Notch-1 and p21WAF1/CIP1 // Int J Cancer. 2011. Vol. 129 (8). P. 2042–2049. 21. Wu Y., Liu S., Xin H. et al. Up-regulation of microRNA-145 promotes differentiation by repressing OCT4 in human endometrial adenocarcinoma cells // Cancer. 2011. Vol. 117 (17). P. 3989–3998. 22. Peng S., Maihle N. J., Huang Y. Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer // Oncogene. 2010. Vol. 29 (14). P. 2153–2159. 23. Zhou X., Zhou Y. P., Huang G. R. et al. Expression of the stem cell marker, Nanog, in human endometrial adenocarcinoma // Int J Gynecol Pathol. 2011. Vol. 30 (3). P. 262–270. 24. Yilmaz E., Celik O., Simsek Y. C-Kit protooncogene expression in endometrial hyperplasia and endometrial cancer // Arch Gynecol Obstet. 2012. Vol. 286 (1). P. 197–200. 25. Kyo S., Kato K. Endometrial Cancer Stem Cell as a Potential Therapeutic Target // Semin Reprod Med. 2015. Vol. 33 (5). P. 341–349. 26. Zhong G., Wang Y., Liu X. Expression of HOXA10 in Endo-metrial Hyperplasia and Adenocarcinoma and Regulation by Sex Hormones In Vitro // Int J Gynecol Cancer. 2011. Vol. 21 (5). P. 800–805. 27. Fambrini M., Bussani C., Sorbi F. et al. Methylation of the HOXA10 homeobox gene promoter is associated with endometrial cancer: a pilot study // J Obstet Gynaecol. 2013. Vol. 33. P. 519–520. 28. Burgos-Ojeda D., Rueda B. R., Buckanovich R. J. Ovarian cancer stem cell markers: prognostic and therapeutic implications // Cancer Lett. 2012.Vol. 322 (1) P. 1–7. 29. Luo L., Zeng J., Liang B. et al. Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome // Exp Mol Pathol. 2011. Vol. 91 (2). P. 596–602. 30. Mundhenke C., Weigel M. T., Sturner K. H. et al. Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects // J Cancer Res Clin Oncol. 2008. Vol. 134 (12). P. 1397–1405. 31. Мамаева Г. М. Клиническая характеристика больных и функциональная морфология яичников при гиперплазиях эндометрия: Автореф. дисс. … канд. мед. наук. М., 1987. 24 с. [Mamayeva G. M. Klinicheskaya kharakteristika bol’nykh i funktsional’naya morfologiya yaichnikov pri giperplaziyakh endometriya: Avtoref. diss. … kand. med. nauk. M., 1987. 24 s. (in Russian)]. 32. Станоевич И. В. Дифференциальный подход к диагностике и лечению гиперплазии эндометрия у женщин позднего репродуктивного и перименопаузального возраста: Автореф. дисс. … канд. мед. наук. М., 2007. 160 с. [Stanoyevich I. V. Differentsial’nyy podkhod k diagnostike i lecheniyu giperplazii endometriya u zhenshchin pozdnego reproduktivnogo i perimenopauzal’nogo vozrasta: Avtoref. diss. … kand. med. nauk. M., 2007. 160 s. (in Russian)]. 33. Edris F., Vilos G. A., Al-Mubarak A. et al. Resectoscopic surgery may be an alternative to hysterectomy in high-risk women with atypical endometrial hyperplasia // J Minim Invasive Gynecol. 2007. Vol. 14 (1). P. 68–73. 34. Gallos I. D., Alazzam M., Clark T. J. et al. Management of endometrial hyperplasia. Green- top Guideline № 67. RCOG/BSGE Joint Guideline, 2016. 30 p. 35. Agorastos T., Bontis J., Vakiani A. et al. Treatment of endometrial hyperplasias with gonadotropin-releasing hormone agonists: pathological, clinical, morphometric, and DNA-cytometric data // Gynecol Oncol. 1997.Vol. 65. P. 102–114.